Integra LifeSciences (NASDAQ:IART) Releases Q4 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its fourth quarter earnings guidance on Monday. The company provided earnings per share guidance of $0.81-0.89 for the period, compared to the consensus earnings per share estimate of $0.87. The company issued revenue guidance of $441-451 million, compared to the consensus revenue estimate of $448.48 million. Integra LifeSciences also updated its FY 2024 guidance to 2.410-2.490 EPS.

Integra LifeSciences Stock Down 3.2 %

Shares of NASDAQ IART traded down $0.86 during midday trading on Thursday, reaching $25.84. 161,296 shares of the company’s stock traded hands, compared to its average volume of 1,100,591. The company has a market cap of $2.00 billion, a price-to-earnings ratio of -289.67, a P/E/G ratio of 0.82 and a beta of 1.08. Integra LifeSciences has a one year low of $16.81 and a one year high of $45.42. The company has a quick ratio of 2.10, a current ratio of 3.39 and a debt-to-equity ratio of 1.17. The stock’s 50 day simple moving average is $18.90 and its 200-day simple moving average is $24.40.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.02. The business had revenue of $380.80 million for the quarter, compared to analysts’ expectations of $375.81 million. Integra LifeSciences had a positive return on equity of 12.25% and a negative net margin of 0.42%. The business’s revenue for the quarter was down .4% on a year-over-year basis. During the same quarter last year, the firm earned $0.76 EPS. On average, analysts predict that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on IART shares. Morgan Stanley increased their price target on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research report on Monday, July 15th. Bank of America decreased their target price on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th. BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Citigroup increased their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a report on Tuesday. Finally, Truist Financial dropped their target price on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Integra LifeSciences currently has an average rating of “Hold” and an average target price of $27.25.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.